G

Genus

Global animal genetics and breeding technology

Key Account Manager

Full-TimeDeadline 10/9/27
$95k - $150k+ Commission
Expert
Bachelor's
North Carolina, USA+2 moreMore locations: Ohio, USA | Indiana, USA
RemoteIdeally based in Indiana, Ohio, or North Carolina; approximately 50% domestic travel required.
Sales & Account ManagementAccount Management
No H1B Sponsorship

About the job

Requirements
  • A bachelor's degree in Animal Science or a related field.
  • Authorization to work in the United States without current or future employer sponsorship.
  • At least 10 years of experience in swine sales.
  • A strong understanding of production metrics and their business impact.
  • Financial management experience.
  • Experience developing, managing, and delivering annual budgets.
  • Proven ability to build and maintain relationships with key accounts.
  • Experience engaging stakeholders at multiple levels within customer organizations.
  • Experience leading cross-functional account teams.
  • Strategic account planning experience.
  • Ability to identify growth opportunities.
  • Pipeline management experience.
  • Experience executing customer-specific business strategies.
  • Strong negotiation skills.
  • Ability to influence decision-makers.
  • Contract management experience.
  • A track record of driving mutually beneficial outcomes.
  • At least 3 years of experience using Microsoft Office Suite, customer relationship management platforms, Dynamics, Power BI, and customer engagement tools.
  • Excellent communication and presentation skills.
  • Ability to articulate value propositions effectively.
  • Experience conducting high-impact customer engagements.
  • Ability to interpret data and identify trends.
  • Strong analytical decision-making skills.
  • Ability to translate insights into actionable business solutions.
  • Experience collaborating across technical, operations, and commercial teams.
  • Ability to work independently while influencing cross-functional stakeholders.
  • Strong organizational and time management skills.
  • Ability to manage multiple priorities in a fast-paced environment.
Responsibilities
  • Support the Key Account Director in developing strategic customer initiatives to achieve profit targets and customer goals.
  • Develop and maintain favorable relationships with new clients to increase revenue.
  • Maintain and enhance relationships with key accounts to drive revenue and profit growth.
  • Use analytical thinking to recommend product or service enhancements or modifications, identify customer needs, and develop solutions that improve customer satisfaction and sales potential.
  • Work with customer interfaces within accounts to influence, develop, and implement improved ways of realizing genetic performance potential on customer farms.
  • Prepare and manage the annual budget for the area of responsibility, monitoring and adjusting sales operations to meet forecasts.
  • Negotiate, sustain, and renew customer contracts while ensuring customer satisfaction and loyalty.
  • Communicate and sell the value proposition to key industry contacts, including customers and prospects, to drive business growth.
  • Identify and convert prospects and opportunities into new business.
  • Lead teams or projects to grow business and gain market share, leading by example.
  • Inform customers about new product or service offerings and pricing.
  • Develop account plans and use internal resources to implement actions that achieve growth and profitability in assigned accounts and the area of responsibility.
  • Create, monitor, and adjust lead-generation plans to maintain a robust sales opportunity pipeline.
  • Research market trends, maintain awareness of industry and competitor information, and analyze data and sales statistics.
  • Prepare and present reports to stakeholders on the current status of the company's relationships with key accounts.
  • Travel approximately 50% domestically.

About the company

Genus is a global animal-genetics company focused on improving cattle and pig performance through breeding and genetic technologies. It operates two main units, ABS Global for bovine genetics and PIC for porcine genetics, offering breeding animals, reproduction services, and gene-editing and next-generation breeding tools. Its products work by combining genetics, reproductive biology, and data-driven selection to produce healthier herds, higher-quality food, and more efficient production. Genus differentiates itself through its global scale (operations in 30 countries and distribution to over 50 markets), its specialized units for cattle and pigs, and its integration of science with practical farming solutions. Its goal is to sustainably nourish the world by improving animal health, food quality, and the resilience of the global food system, while delivering value to customers and upholding ethical, collaborative values.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Basingstoke, United Kingdom

Founded

1933

Get referred to Genus

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Genus said 14 July 2026 FY26 results should beat consensus and cut leverage.
  • The Chinese porcine joint venture delivered about £111 million cash in FY26.
  • ABS posted double-digit profit growth in FY26, helped by the Value Acceleration Programme.

What critics are saying

  • North American PIC volumes weakened in FY26 from customer disease challenges.
  • Genus still depends on further approvals before selling PRRS-resistant pigs in Canada.
  • If EU and U.S. adoption stalls, PRRS-resistant pigs stay a stranded platform.

What makes Genus unique

  • PIC’s PRRS-resistant pigs won Canada approval on 23 January 2026.
  • Genus monetizes elite genetics through recurring royalties, not commodity livestock sales.
  • ABS and PIC combine bovine and porcine genetics across 100-plus countries.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Parental Leave
  • Employee Stock Purchase Plan
  • Paid Holidays
  • Paid Vacation

Company News

Associated Press
Jan 23rd, 2026
Canada approves PRRSV-resistant pigs for food and feed to cut farm losses and antibiotic use

Canada has approved genetically engineered pigs resistant to porcine reproductive and respiratory syndrome viruses for use in food and feed. Health Canada and the Canadian Food Inspection Agency completed independent safety assessments following applications from Genus PLC and PIC Canada, concluding the pigs are as safe and nutritious as conventional pork. The approval addresses PRRSV, one of the most devastating virus classes affecting farmed pigs, which causes severe symptoms including breathing problems, fever and stillborn piglets. There are currently no effective treatments available. Genus PLC's PRRSV-resistant pigs are already approved in the US, Brazil, Colombia and the Dominican Republic. However, the company will not sell these pigs in Canada until receiving regulatory authorisation in other key markets. Canada's swine industry generated over $6.3 billion in farm cash receipts in 2024.

TipRanks
Oct 21st, 2024
Genus plc CFO to Retire, Successor Search Underway

Genus plc, a global leader in animal genetics, has announced the upcoming retirement of its Chief Financial Officer, Alison Henriksen, who will leave her role in July 2025 after five years with the company.

PharmiWeb
Sep 7th, 2023
Genus Plc Preliminary Results For The Year Ended 30 June 2023

SOLID PERFORMANCE AND GOOD STRATEGIC PROGRESSWEBCAST AVAILABLE AT 7:01AM GMT, 2.01 ESTLONDON--(BUSINESS WIRE)--Genus (LSE:GNS), a leading global animal genetics company, today announces its preliminary results for the year ended 30 June 2023. The full report has been made available on the investors section of the Genus plc website. The Company will discuss its corporate, operational and financial highlights in a pre-recorded webcast at 7:01 AM GMT, 2.01 EST.Commenting on the performance and outlook, Jorgen Kokke, Chief Executive Officer, said:“The Group achieved a strong operational performance despite ongoing challenging market conditions for producers in several important markets. Revenues grew in all regions and both PIC and ABS delivered profit growth. This also enabled us to deliver record adjusted EBITDA and good cashflow for the Group. Growth in R&D investments, primarily due to the strategically important gene editing work and expansion of PIC’s elite farms, as well as higher interest costs, resulted in adjusted profit before tax consistent with the prior year.“PIC’s performance was particularly impressive, achieving a record adjusted operating profit for the year

MarketWatch
Apr 3rd, 2023
Genus Names Jorgen Kokke as Chief Executive Officer Designate

Genus PLC said Monday that it has appointed Jorgen Kokke as chief executive officer designate, effective from May 2.

PharmiWeb
Sep 8th, 2022
Genus Plc Reports Preliminary Results For The Year Ended 30 June 2022

Continued Strategic Progress in Challenging Markets. Webcast Available at 7:01AM BST, 2.01 EDT